- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05720988
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Tagraxofusp-Based Therapy to Eradicate Measurable Residual Disease of Acute Myelogenous Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the safety and tolerability of tagraxofusp-erzs (tagraxofusp) with or without azacitidine in participants with acute myeloid leukemia (AML) in remission who are planned to undergo allogeneic hematopoietic cell transplantation (alloHCT).
SECONDARY OBJECTIVES:
I. To estimate the rate of conversion from measurable residual disease (MRD) positive (>= 0.01% by multiparametric flow cytometry [MPFC]) pre-investigational therapy to MRD negative (=< 0.01% by MPFC) after 1 or 2 cycles of investigational therapy.
II. To estimate the rate of conversion from MRD positive (>= 0.01% by MPFC) pre-investigational therapy to MRD negative (=< 0.01% by MPFC) post-investigational therapy within 30 days prior to initiation of transplant conditioning regimen and at day +100 following alloHCT.
III. To evaluate if adverse effects of this investigational combination leads to delays in alloHCT.
IV. To evaluate if this investigational therapy results in liver toxicities after alloHCT such as sinusoidal obstruction syndrome.
V. To evaluate relapse rate following alloHCT in participants who receive investigational therapy.
VI. To evaluate MRD progression following alloHCT in participants who receive investigational therapy.
VII. To evaluate 1-year survival following alloHCT in participants who receive investigational therapy.
EXPLORATORY OBJECTIVES:
I. To estimate the rate of conversion from MRD positive to MRD negative by means of next generation sequencing.
II. To describe the level of CD123 expression on leukemia blasts in the bone marrow specimen at diagnosis and/or time of relapse and the association with achievement of MRD negativity post-investigational therapy.
III. To evaluate the number of days to full donor T-cell chimerism following alloHCT.
OUTLINE: This is a dose-escalation study of tagraxofusp-erzs . Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients receive tagraxofusp-erzs intravenously (IV) once daily (QD) over 15 minutes on days 1-5. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
COHORT II: Patients receive azacitidine subcutaneously (SC) daily on days 1-5 and tagraxofusp-erzs IV QD over 15 minutes on days 8-12. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 12 months.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Habtemariam,Bruck
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >= 18 years
AML in first or second remission, including:
- Complete remission (CR), defined as bone marrow blasts < 5%, absence of circulating blasts, absence of extramedullary disease, absolute neutrophil count (ANC) >= 1,000/uL, platelet count > 100,000/uL
- Complete remission with incomplete hematologic recovery (CRi), defined as all CR criteria except for residual neutropenia (ANC < 1,000/uL) or residual thrombocytopenia (platelet count < 100,000/uL)
- Morphologic leukemia-free state with adequate marrow recovery, defined as bone marrow blasts < 5%, ANC >= 500/uL, and platelet count >= 20,000/uL
Minimal residual disease positive >= 0.01% based on MPFC
- For participants in first remission, MRD positivity at any point from time of establishing first remission onward while still in first remission
- For participants in second remission, MRD positivity at any point from time of establishing second remission onward while still in second remission
- MRD must be repeated and remain positive if additional treatment is given prior to enrollment
CD123 positivity on flow cytometry (partial, dim, or bright) from either:
- Conventional flow cytometry on marrow specimen from time of original diagnosis or first relapse
- High-sensitivity multiparametric flow cytometry on marrow specimen from time of MRD positivity
- Eastern Cooperative Oncology Group (ECOG) 0-2
- Serum albumin level >= 3.2 g/dL in the absence of receiving albumin infusion
- Serum total bilirubin =< 1.5 mg/dL, unless considered due to Gilbert's disease or medication effect
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase =< 2.5 times the upper limit of normal, unless considered due to medication effect (eg, azole therapy)
- Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) =< 1.8 mg/dL
- Ability to give full informed consent
- Females of reproductive potential (postmenopausal for less than 24 consecutive months) must have a negative pregnancy test within 1 week of initiating treatment and may not be breastfeeding
Exclusion Criteria:
- MRD negativity < 0.01% at screening
- Intensive AML therapy within the past 14 days, or non-intensive targeted therapy within the past 7 days
- Cord blood as donor source
- Second malignancy that would be expected to limit survival within less than 2 years
Cardiovascular disease that would result in high risk for toxicity, including:
- Uncontrolled or New York Heart Association (NYHA) class III or VI congestive heart failure
- Recurrent or uncontrolled angina
- Unstable angina, myocardial infarction, or stroke in past 6 months
- Uncontrolled hypertension
- Arrhythmia not controlled by medication
- Left ventricular ejection fraction < 50%
- History of coronary stent placement that requires mandatory continuation of dual antiplatelet therapy
- Uncontrolled intercurrent illness that includes but is not limited to: uncontrolled infection, disseminated intravascular coagulation, psychiatric illness/compliance issues that would limit compliance with study protocol
- Any medical condition that in the opinion of the investigator places the participant at unacceptable risk for toxicity to investigational therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cohort I (tagraxofusp-erzs)
Patients receive tagraxofusp-erzs IV QD over 15 minutes on days 1-5.
Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
|
Experimental: Cohort II (azacitidine, tagraxofusp-erzs)
Patients receive azacitidine SC daily on days 1-5 and tagraxofusp-erzs IV QD over 15 minutes on days 8-12.
Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
|
Given SC
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity
Time Frame: Up to 42 days
|
Grade >= 3 toxicity using Common Terminology Criteria for Adverse Events version 5.0 or severe persistent hematologic toxicity defined as absolute neutrophil count (ANC) < 500/uL OR platelet count < 10,000/uL in participants that have morphologic leukemia-free state (bone marrow blasts < 5%) are conditions for a dose limiting toxicity.
|
Up to 42 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurable residual disease (MRD)
Time Frame: At the end of cycle 1 and cycle 2 (each cycle is 28 days).
|
As measured by the University of Washington multiparametric flow cytometry (MPFC) assay with sensitivity of 0.01%
|
At the end of cycle 1 and cycle 2 (each cycle is 28 days).
|
MRD
Time Frame: Within 30 days prior to initiation of transplant conditioning regimen and at day 100 after transplant
|
As measured by the University of Washington MPFC assay with sensitivity of 0.01%.
|
Within 30 days prior to initiation of transplant conditioning regimen and at day 100 after transplant
|
Number of days between investigational regimen day 28 and initiation of transplant conditioning regimen
Time Frame: Between investigational regimen day 28 and initiation of transplant conditioning regimen, through study completion, an average of 1 year.
|
Between investigational regimen day 28 and initiation of transplant conditioning regimen, through study completion, an average of 1 year.
|
|
Rate of sinusoidal obstruction syndrome
Time Frame: up to 1 year following investigational therapy
|
up to 1 year following investigational therapy
|
|
Relapse
Time Frame: Up to 1 year
|
As defined by International Working Group criteria: the relapse rate and median duration of remission following allogeneic hematopoietic cell transplantation (HCT) will be reported along with an exact 95% confidence interval.
|
Up to 1 year
|
MRD progression
Time Frame: Up to 1 year
|
Defined by presence of leukemia blasts >0.01% at any time after achieving MRD negativity (<0.01%).
|
Up to 1 year
|
Overall survival
Time Frame: 1 year after transplant
|
Kaplan-Meier methods will estimate the overall survival at 1 year following allogeneic (allo)HCT.
This analysis will be performed using the FAS.
The 1-year survival estimate will be reported along with a 95% confidence interval.
|
1 year after transplant
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CD123 expression via immunohistochemical stain on leukemia blasts in the bone marrow specimen
Time Frame: at time of diagnosis or relapse and following cycle 1 and cycle 2 (each cycle is 28 days).
|
CD123 expression, on the original bone marrow specimen at time of diagnosis or time of relapse and the bone marrow specimen at time of MRD negativity, will be described as bright, dim, partial, or negative; and summarized by mean, median, standard deviation, and interquartile range.
|
at time of diagnosis or relapse and following cycle 1 and cycle 2 (each cycle is 28 days).
|
T-cell (CD3) chimerism via short tandem repeat assay
Time Frame: 30, 90, 180, and 365 days after transplant
|
Days to achieve full T-cell chimerism following alloHCT will be characterized by Kaplan-Meier methods along with 95% confidence interval.
|
30, 90, 180, and 365 days after transplant
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Caspian Oliai, MD, UCLA / Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Hematologic Diseases
- Neoplastic Processes
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Neoplasm, Residual
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Azacitidine
Other Study ID Numbers
- 21-001115
- NCI-2021-12912 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Advesya SASNot yet recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryFrance, Sweden, Spain, Germany
-
Keystone Nano, IncMilton S. Hershey Medical Center; University of VirginiaNot yet recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, RefractoryUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Maturation | Adult Acute Myeloid Leukemia Without Maturation | Adult Acute Myelomonocytic Leukemia | Alkylating Agent-Related Acute Myeloid... and other conditionsUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Oryzon Genomics S.A.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
University Hospital, AntwerpRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryBelgium
-
Medical College of WisconsinRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Stanford UniversityCelgene CorporationCompletedAcute Myeloid Leukemia (AML) | Adult Acute Myeloblastic LeukemiaUnited States
Clinical Trials on Azacitidine
-
Shandong Provincial HospitalUnknownMyelodysplastic Syndromes,Acute Myeloid LeukemiaChina
-
TJ Biopharma Co., Ltd.Recruiting
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Celgene CorporationCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)Australia
-
Eisai Inc.TerminatedMyelodysplastic SyndromesUnited States
-
Navy General Hospital, BeijingRecruitingRefractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin LymphomaChina
-
University of BirminghamActive, not recruitingAcute Myeloid Leukemia | MyelodysplasiaUnited Kingdom
-
Nanexa ABUppsala UniversityCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)Sweden
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
CelgeneCompletedMyelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Acute Myelogenous Leukemia (AML)United States
-
CelgeneCompletedMyelodysplastic SyndromesUnited States